Literature DB >> 1153228

Spontaneous regression of melanoma.

V J McGovern.   

Abstract

Primary cutaneous melanoma has a tendency to disappear spontaneously. Histologically the active phase is characterized by a dense infiltrate of lymphocytes similar to that seen in spontaneously disappearing naevi. The regression process may continue until the tumour has been completely destroyed, or it may cease when only a part of the tumour has been destroyed. The lymphocytes disappear when the process halts leaving vascular scar tissue with a variable number of pigment-containing phagocytes. As a result of this a certain number of distinctive clinical patterns can be recognized: (1) An inflammatory nodule with or without pigmentation; (2) scarring in the tumour; (3) several foci of melanoma simulating multicentricity; (4) pigmented lesion with a depigmented halo; (5) pigmented scar with surviving melanoma cells; (6) pigmented scar without surviving tumour cells; and (7) metastatic melanoma with no demonstrable cutaneous primary. Only melanomas with a component of superficial spreading type have been found undergoing spontaneous regression.

Entities:  

Mesh:

Year:  1975        PMID: 1153228     DOI: 10.3109/00313027509092702

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  32 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

Review 2.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

Review 4.  Primary small bowel melanoma. A case report and a review of the literature.

Authors:  K G Spiridakis; E E Polichronaki; E E Sfakianakis; M E Flamourakis; T H Margetousakis; A S Xekalou; G K Lianeris; E S Giannikaki; M S Christodoulakis
Journal:  G Chir       Date:  2015 May-Jun

5.  Metastatic amelanotic melanoma of the jejunum diagnosed on capsule endoscopy.

Authors:  Omair Atiq; Ali S Khan; Gary A Abrams
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-10

6.  Targeting tumor-resident mast cells for effective anti-melanoma immune responses.

Authors:  Susanne Kaesler; Florian Wölbing; Wolfgang Eberhard Kempf; Yuliya Skabytska; Martin Köberle; Thomas Volz; Tobias Sinnberg; Teresa Amaral; Sigrid Möckel; Amir Yazdi; Gisela Metzler; Martin Schaller; Karin Hartmann; Benjamin Weide; Claus Garbe; Hans-Georg Rammensee; Martin Röcken; Tilo Biedermann
Journal:  JCI Insight       Date:  2019-10-03

7.  Natural history of cutaneous malignant melanoma.

Authors:  H A Briele; T K Das Gupta
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

8.  Prognostic value of tumour thickness in cutaneous malignant melanoma.

Authors:  I Jeffrey; P Royston; C Sowter; G Slavin; A Price; A Pomerance; S Goolamali; D Pinto
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

9.  Aire deficiency promotes TRP-1-specific immune rejection of melanoma.

Authors:  Meng-Lei Zhu; Anil Nagavalli; Maureen A Su
Journal:  Cancer Res       Date:  2013-01-31       Impact factor: 12.701

10.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.